We had the pleasure of speaking with Manmeet Ahluwalia about current vaccine options for glioblastoma, including a survivin vaccine (SurVaxM) for newly diagnosed glioblastoma.
Researchers have discovered administering pembrolizumab before surgery is more effective for the treatment of recurrent glioblastoma, than when administering the drug afterwards.
New research has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy.
In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
The article reviews current literature on the use of adoptive immunotherapy for malignant gliomas as well as the
the concept of antitumor activity mediated by CIK cells.
Immunotherapy for glioblastoma has been an area of intense research in recent years – this review looks at the potential of HCMV in the initiation, promotion and progression of tumorigenesis.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.
This Spotlight will explore every corner of neuroimmunology, looking in-depth at the history of the field, new uses for the immune system in a wealth of neurological diseases, and looking ahead at the future of this ever-expanding field.
Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.